Cell-Easy Expands US Footprint with Key Contract Signing for Master Cell Bank (MCB) and Working Cell Bank (WCB) Manufacturing Services.

Toulouse, France, May 14, 2024 –


Cell-Easy, a European Contract Development and Manufacturing Organization (CDMO) specializing in Cell Therapy, announces a significant milestone with the signing of a Cell Bank Development and Manufacturing services contract with a prominent US-based pharmaceutical company. This partnership solidifies its position as a trusted expert in cell-based product development and manufacturing services.


Human cell banking plays a critical role in advancing cell-based therapies, serving as the foundation for product development, regulatory approval, and commercialization. However, the process presents challenges, including maintaining cell viability, ensuring genetic stability, and adhering to stringent regulatory requirements. Addressing these challenges requires expertise in cell culture, cryopreservation, and quality control, along with access to validated providers and scalable manufacturing capabilities.


Cell Easy was chosen for its expertise in the above-mentioned fields:

        • Track record in Cell-Banking: With numerous Cell Banking projects in different cell types using various technologies, Cell-Easy had the track record to convince on its ability to scale-up the process and safeguard cells using the suitable freezing strategy.
        • Managing international supply chains: Cell-Easy has established a network of validated providers to ensure the safe and efficient delivery of cell products, even cross-Atlantic.
        • Competitive Costs: Finding the best path forward, Cell-Easy’s process development experts have been able to streamline the process, reducing the overall costs without compromising on quality. Reduction in manpower, raw material and clean room booking have all been instrumental in providing cost-effective solutions while maintaining the highest standards of excellence in cell bank manufacturing.

By engaging customers in conversations about their current status, needs, and future goals, we effectively tailor proposals to offer diverse pathways forward and fine-tune project scopes to accommodate their constraints. This not only adds tangible value for prospects but also showcases our depth of understanding and expertise. Ultimately, it optimizes the return on investment for their expenditure. This science-driven approach has been instrumental in successfully penetrating the US market.

About Cell-Easy

Cell-Easy is a science-driven CDMO specialized on advanced Cell Therapies.

Cell-Easy offers a broad range of Services, including Process and Analytical development, GMP manufacturing and CMC/Regulatory support for global  Biotechs & Pharmas.

The scientific team and QbD approach enable seamless technology transfer and development for cell-based therapies in the fields of oncology, autoimmune diseases and regenerative medicine (T cells, NK cells, Macrophages, MSCs, HSCs and exosomes)

Explore our services at https://www.cell-easy.com and don’t hesitate to contact us at info@cell-easy.com